Skip to main content

Cancer Causes & Control

Ausgabe 5/2013

Inhalt (22 Artikel)

Open Access Editorial

Eight ways to stay healthy after cancer: an evidence-based message

Kathleen Y. Wolin, Hank Dart, Graham A. Colditz

Original paper

Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer

Jonathan Assayag, Hui Yin, Serge Benayoun, Michael N. Pollak, Samy Suissa, Laurent Azoulay

Original paper

Social support and cancer incidence and mortality: the JPHC study cohort II

Ai Ikeda, Ichiro Kawachi, Hiroyasu Iso, Motoki Iwasaki, Manami Inoue, Shoichiro Tsugane

Original Paper

Serum insulin and C-peptide concentration and breast cancer: a meta-analysis

Philippe Autier, Alice Koechlin, Mathieu Boniol, Patrick Mullie, Geremia Bolli, Julio Rosenstock, Peter Boyle

Original paper

Dietary consumption and diet diversity and risk of developing bladder cancer: results from the South and East China case–control study

Fatima Isa, Li-Ping Xie, Zhiquan Hu, Zhaohui Zhong, Marjolein Hemelt, Raoul C. Reulen, Y. C. Wong, Po-Chor Tam, Kai Yang, Chao Chai, Xing Zeng, Yilan Deng, Wei-De Zhong, Maurice P. Zeegers

Original paper

An analysis of competing mortality risks among colorectal cancer survivors in Queensland, 1996–2009

Paramita Dasgupta, Danny R. Youlden, Peter D. Baade

Open Access Original paper

Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis

Giovanni Brandi, Stefania Di Girolamo, Andrea Farioli, Francesco de Rosa, Stefania Curti, Antonio Daniele Pinna, Giorgio Ercolani, Francesco Saverio Violante, Guido Biasco, Stefano Mattioli

Original paper

Quantitative exposure metrics for sleep disturbance and their association with breast cancer risk

Jennifer Girschik, Lin Fritschi, Thomas C. Erren, Jane Heyworth

Original paper

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status

Maria Simonsson, Viktoria Söderlind, Maria Henningson, Maria Hjertberg, Carsten Rose, Christian Ingvar, Helena Jernström

Original paper

Associations of tea and coffee consumption with prostate cancer risk

Milan S. Geybels, Marian L. Neuhouser, Janet L. Stanford

Original paper

Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand

Michelle C. Turner, Daniel Krewski, Bruce K. Armstrong, Angela Chetrit, Graham G. Giles, Martine Hours, Mary L. McBride, Marie-Élise Parent, Siegal Sadetzki, Jack Siemiatycki, Alistair Woodward, Elisabeth Cardis

Original paper

Do diagnostic and treatment delays for colorectal cancer increase risk of death?

Sandi L. Pruitt, Amy Jo Harzke, Nicholas O. Davidson, Mario Schootman

Original paper

Clinical trial discussion, referral, and recruitment: physician, patient, and system factors

Celia P. Kaplan, Anna Maria Nápoles, Daniel Dohan, E. Shelley Hwang, Michelle Melisko, Dana Nickleach, Jessica Ann Quinn, Jennifer Haas

Original paper

Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies

Mette T. Faber, Susanne K. Kjær, Christian Dehlendorff, Jenny Chang-Claude, Klaus K. Andersen, Estrid Høgdall, Penelope M. Webb, Susan J. Jordan, Mary Anne Rossing, Jennifer A. Doherty, Galina Lurie, Pamela J. Thompson, Michael E. Carney, Marc T. Goodman, Roberta B. Ness, Francesmary Modugno, Robert P. Edwards, Clareann H. Bunker, Ellen L. Goode, Brooke L. Fridley, Robert A. Vierkant, Melissa C. Larson, Joellen Schildkraut, Daniel W. Cramer, Kathryn L. Terry, Allison F. Vitonis, Elisa V. Bandera, Sara H. Olson, Melony King, Urmila Chandran, Lambertus A. Kiemeney, Leon F. A. G. Massuger, Anne M. van Altena, Sita H. Vermeulen, Louise Brinton, Nicolas Wentzensen, Jolanta Lissowska, Hannah P. Yang, Kirsten B. Moysich, Kunle Odunsi, Karin Kasza, Oluwatosin Odunsi-Akanji, Honglin Song, Paul Pharaoh, Mitul Shah, Alice S. Whittemore, Valerie McGuire, Weiva Sieh, Rebecca Sutphen, Usha Menon, Simon A. Gayther, Susan J. Ramus, Aleksandra Gentry-Maharaj, Celeste Leigh Pearce, Anna H. Wu, Malcolm C. Pike, Harvey A. Risch, Allan Jensen

Original paper

Dietary intake of vegetables, folate, and antioxidants and the risk of Barrett’s esophagus

Li Jiao, Jennifer R. Kramer, Massimo Rugge, Paola Parente, Gordana Verstovsek, Abeer Alsarraj, Hashem B. El-Serag

Original paper

Prospective cohort studies of bowel movement frequency and laxative use and colorectal cancer incidence in US women and men

Xuehong Zhang, Kana Wu, Eunyoung Cho, Jing Ma, Andrew T. Chan, Xiang Gao, Walter C. Willett, Charles S. Fuchs, Edward L. Giovannucci

Original paper

Anthropometric factors in relation to risk of glioma

Rebecca B. Little, Melissa H. Madden, Reid C. Thompson, Jeffrey J. Olson, Renato V. LaRocca, Edward Pan, James E. Browning, Kathleen M. Egan, L. Burton Nabors

Original paper

Anthropometric factors, physical activity, and breast cancer risk in relation to hormone receptor and menopausal status in Japanese women: a case–control study

Masaaki Kawai, Yoichiro Kakugawa, Yoshikazu Nishino, Yohei Hamanaka, Noriaki Ohuchi, Yuko Minami

Original paper

Androgenetic alopecia at various ages and prostate cancer risk in an equal-access multiethnic case–control series of veterans

Jean-Alfred Thomas, Jodi A. Antonelli, Lionel L. Banez, Catherine Hoyo, Delores Grant, Wendy Demark-Wahnefried, Elizabeth A. Platz, Leah Gerber, Kathryn Shuler, Enwono Eyoh, Elizabeth Calloway, Stephen J. Freedland

Brief report

Association between allergies, asthma, and breast cancer risk among women in Ontario, Canada

Elizabeth C. Lowcock, Michelle Cotterchio, Noor Ahmad

Brief report

Changes in access to screening mammography, 2008–2011

Elena B. Elkin, J. Paige Nobles, Laura C. Pinheiro, Coral L. Atoria, Deborah Schrag

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.